Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 - NTRK1 |
| Therapy | Larotrectinib |
| Indication/Tumor Type | infant-type hemispheric glioma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 - NTRK1 | infant-type hemispheric glioma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib) treatment resulted in an overall 65.8% size decrease in the enhancing lesions in a pediatric patient with infant-type hemispheric glioma harboring TP53-NTRK1 (PMID: 37666486). | 37666486 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37666486) | Off-target Resistance to Larotrectinib in two Patients with NTRK Fusion-positive Pediatric Solid Tumors. | Full reference... |